Figure 1.

AMPK inactivation slows the progression of SHH-driven medulloblastoma

(A) PRKAA1 mRNA expression in clinical medulloblastoma samples of indicated subgroups, p values determined by 1-way ANOVA comparing the indicated pairs. In this box and whiskers plot, boxes indicate the upper and lower quartiles, the horizontal line between boxes indicates the mean, and whiskers inidcate 150% of the interquartile range, limited by the total range.

(B and C) Representative sagittal brain sections from G-Smo and G-Smo^AMPK mice show similar site of tumor formation and hypercellular tumor pathology.

(D) Increased survival time in G-Smo^AMPK mice compared to G-Smo controls with intact AMPK. Survival times in (D) were compared by Log-Rank test.

(E) Representative IF on sagittal sections of G-Smo and G-Smo^AMPK medulloblastomas, showing pRB and NEUN expression.

(F) Quantification of the fractions of tumor cells expressing the indicated marker in 6 replicate G-Smo tumors and 5 replicate G-Smo^AMPK tumors of each genotype, compared by Student’s t test. Bars = 3 mm in (B) and 50 μm in (C and E).